Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    IS05 - Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer

    • 14:15 - 15:15
    • 1/28/2021
    • Location: Industry Symposia Auditorium (via Industry Hub)
    • Not for CME Credit
    • Type: Industry Symposium
    • Track:
    • +

      IS05.03 - Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer

      14:30 - 14:45  |  Presenter: Roy S. Herbst

      • Abstract

      No abstract available for this presentation

    • +

      IS05.05 - Q&A and Closing Remarks

      15:00 - 15:15  |  Presenter: Rina Hui, Roy S. Herbst, Corey J. Langer

      • Abstract

      No abstract available for this presentation

  • +

    FP13 - Immunotherapy (Phase II/III Trials)

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Type: Posters (Featured)
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      FP13.01 - 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC

      00:00 - 00:00  |  Presenter: Roy S. Herbst

      • Abstract

      Loading...

    • +

      FP13.03 - IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC

      00:00 - 00:00  |  Presenter: Roy S. Herbst

      • Abstract

      Loading...

  • +

    P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
    • +

      P01.21 - ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era

      00:00 - 00:00  |  Presenter: Jordi Remon

      • Abstract

      Loading...

  • +

    P09 - Health Services Research/Health Economics - Real World Outcomes

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Health Services Research/Health Economics
    • +

      P09.55 - A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung Cancer

      00:00 - 00:00  |  Presenter: Guneet Walia

      • Abstract

      Loading...

  • +

    OA01 - Established Drugs in Special Populations and New Drugs in Established Populations

    • 09:15 - 10:15
    • 1/29/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      OA01.04 - Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A

      09:25 - 09:35  |  Presenter: Fred R Hirsch

      • Abstract

      Loading...

  • +

    ES02 - Pro-Con: Do We Need Biomarkers to Guide the Choice of Immunotherapy Treatment?

    • 10:30 - 11:30
    • 1/29/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Educational Session
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      ES02.03 - We Should Use IO Alone as Maintenance

      11:00 - 11:15  |  Presenter: Roy S. Herbst

      • Abstract

      No abstract available for this presentation

  • +

    OA06 - Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy

    • 16:45 - 17:45
    • 1/29/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Early Stage/Localized Disease
    • +

      OA06.03 - Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC

      16:45 - 16:55  |  Presenter: Margarita Majem

      • Abstract

      Loading...

    • +

      OA06.04 - Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC

      16:55 - 17:05  |  Presenter: Yi-long Wu

      • Abstract

      Loading...

  • +

    MA08 - Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non Small Cell Lung Carcinoma

    • 16:45 - 17:45
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
    • +

      MA08.10 - LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis

      17:20 - 17:25  |  Presenter: Philip Christopher Mack

      • Abstract

      Loading...

  • +

    MA11 - Expanding Targetable Genetic Alterations in NSCLC

    • 14:15 - 15:15
    • 1/31/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Targeted Therapy - Clinically Focused
    • +

      MA11.10 - Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400)

      14:50 - 14:55  |  Presenter: David Kozono

      • Abstract

      Loading...